Chimerix (NASDAQ:CMRX - Get Free Report)'s stock had its "buy" rating restated by research analysts at HC Wainwright in a research note issued to investors on Monday,Benzinga reports. They presently have a $11.00 price objective on the biopharmaceutical company's stock. HC Wainwright's price objective points to a potential upside of 219.77% from the stock's current price.
Separately, Wedbush reaffirmed an "outperform" rating and set a $6.00 price target on shares of Chimerix in a report on Tuesday, December 10th.
Get Our Latest Analysis on Chimerix
Chimerix Trading Down 0.6 %
Shares of Chimerix stock traded down $0.02 during trading on Monday, hitting $3.44. 1,599,552 shares of the stock were exchanged, compared to its average volume of 1,271,378. The company has a fifty day moving average price of $1.50 and a 200-day moving average price of $1.11. The stock has a market capitalization of $309.38 million, a price-to-earnings ratio of -3.66 and a beta of 1.02. Chimerix has a 1-year low of $0.75 and a 1-year high of $3.66.
Institutional Investors Weigh In On Chimerix
A number of institutional investors have recently made changes to their positions in CMRX. Marshall Wace LLP acquired a new stake in shares of Chimerix during the second quarter worth $137,000. Valeo Financial Advisors LLC increased its position in Chimerix by 566.9% during the third quarter. Valeo Financial Advisors LLC now owns 81,766 shares of the biopharmaceutical company's stock worth $76,000 after acquiring an additional 69,505 shares during the period. Finally, Connor Clark & Lunn Investment Management Ltd. raised its stake in Chimerix by 66.8% in the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 344,712 shares of the biopharmaceutical company's stock worth $321,000 after purchasing an additional 138,098 shares in the last quarter. Institutional investors own 45.42% of the company's stock.
Chimerix Company Profile
(
Get Free Report)
Chimerix, Inc, a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors.
See Also
Before you consider Chimerix, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Chimerix wasn't on the list.
While Chimerix currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
